Related references
Note: Only part of the references are listed.Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy
Brandon M. Bordeau et al.
CANCER RESEARCH (2021)
Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy
Jose F. Ponte et al.
MOLECULAR CANCER THERAPEUTICS (2021)
An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens
Bruna Menezes et al.
AAPS JOURNAL (2020)
Increased Tumor Penetration of Single-Domain Antibody-Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models
Ian Nessler et al.
CANCER RESEARCH (2020)
Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers
Guolan Lu et al.
CLINICAL CANCER RESEARCH (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study
Ning Sun et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates
Guolan Lu et al.
NATURE COMMUNICATIONS (2020)
Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle
Imke H. Bartelink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues
Donglu Zhang et al.
DRUG METABOLISM AND DISPOSITION (2019)
Immunogenic cell death in cancer therapy: Present and emerging inducers
Jingyi Zhou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation
Nicholas C. Yoder et al.
MOLECULAR PHARMACEUTICS (2019)
A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects
Jackson K. Burton et al.
AAPS JOURNAL (2019)
Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
Ricarda M. Hoffmann et al.
ONCOIMMUNOLOGY (2018)
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
Tomomi Nakayama Iwata et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival
Cornelius Cilliers et al.
CANCER RESEARCH (2018)
Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy
Eshita Khera et al.
MOLECULAR SYSTEMS DESIGN & ENGINEERING (2018)
Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates
Martin Pabst et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Peter C. Thuss-Patience et al.
LANCET ONCOLOGY (2017)
Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies
Jonathan Rios-Doria et al.
CANCER RESEARCH (2017)
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Y. J. Bang et al.
ANNALS OF ONCOLOGY (2017)
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy
Cornelius Cilliers et al.
AAPS JOURNAL (2016)
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
Pia M. Challita-Eid et al.
CANCER RESEARCH (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets
John J. Rhoden et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
Heather Donaghy
MABS (2016)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates
Siddharth Sukumaran et al.
PHARMACEUTICAL RESEARCH (2015)
Site-Specific Trastuzumab Maytansinoid Antibody-Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering
Thomas H. Pillow et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates
Puja Sapra et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2013)
Differential Effects of Predosing on Tumor and Tissue Uptake of an 111In-Labeled Anti-TENB2 Antibody-Drug Conjugate
C. Andrew Boswell et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Dose dependence of intratumoral perivascular distribution of monoclonal antibodies
John J. Rhoden et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Quantitating Antibody Uptake In Vivo: Conditional Dependence on Antigen Expression Levels
Greg M. Thurber et al.
MOLECULAR IMAGING AND BIOLOGY (2011)
Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Jagath R. Junutula et al.
CLINICAL CANCER RESEARCH (2010)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice
Nelson L. Jumbe et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2010)
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Michael M. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
Yeast surface display for protein engineering and characterization
S. Annie Gai et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2007)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
New approaches to antibody therapy
LM Weiner et al.
ONCOGENE (2000)
Share Paper
